PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

As India grapples with an escalating diabetes crisis, with 101 million1 diagnosed and 136 million with pre-diabetes, the ...

Diabetic retinopathy is a common complication of diabetes, which manifests as a potentially severe eye disease that can lead ...

Exonate has announced plans to initiate a phase 2b clinical trial of its lead candidate EXN407, a topical SRPK1 inhibitor, ...

A new study published in the Nature Scientific Reports showed that compared to kidney recipients who got preemptive transplants, individuals who experienced dialysis prior to transplantation are ...

Statistical analysis showed a strong association between advanced diabetic retinopathy and an increased likelihood of heart ...

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...